key: cord-0050840-e8e5s5ti
authors: Ghosal, Samit
title: Selecting antihyperglycemic agents with proven safety: A must in COVID-19 era
date: 2020-08-21
journal: Indian J Med Sci
DOI: 10.25259/ijms_76_2020
sha: 48523a3be8592622e1ab5a365c58c5de18af4d89
doc_id: 50840
cord_uid: e8e5s5ti

nan

There is ample evidence of arrhythmias induced by SARS-CoV-2 infection per se with prolongation of QTc interval as one of the many mechanisms. [2] This issue is compounded by the use of medications with known predilection for QTc prolongation. There has been a push for the use of hydroxychloroquine as an antihyperglycemic agent proactively in patients with type 2 diabetes mellitus. [3] In addition, drugs like teneligliptin which have not passed the thorough QTc prolongation studies are prescribed in large numbers in India. [4] I propose the use of antihyperglycemic agents with proven cardiorenal benefits from cardiovascular outcome trials (CVOTs) and proven safety derived from thorough QTc trials be considered preferentially in the management of type 2 diabetes. It would also be prudent to switch all patients receiving drugs without safety signals from dedicated CVOTs, for example, teneligliptin, hydroxychloroquine (as antihyperglycemic agent), and remogliflozin, to drugs with proven safety [ Table 1 ].

There has been a flurry of publications implicating medications with the potential to upregulate angiotensin-converting enzyme (ACE2), which is known to be the human receptor for SARS-CoV-2 spike protein. Glucagon-like peptide receptor analog and dipeptidyl peptidase-4 inhibitors have been implicated as offenders. [5] However, the recent publications with the use of ACE inhibitors and ARBs have suggested otherwise. [6] The anti-inflammatory benefits of these agents overwhelm the potential harm associated with their ability to upregulating ACE2.

In light of all the recently available and evolving evidences, choosing antihyperglycemic agents prudently with stress on proven safety and anti-inflammatory properties rather than taking a myopic glucocentric view would reflect good clinical practice. 

Prevalence and impact of diabetes among people infected with SARS-CoV-2

Cardiac and arrhythmic complications in patients with COVID-19

Expert group consensus opinion: Role of antiinflammatory agents in the management of Type-2 diabetes (T2D)

Thorough QTc Study": Thorough enough?

COVID-19, diabetes mellitus and ACE2: The conundrum

The Effect of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Death and Severity of Disease in Patients with Coronavirus Disease 2019 (COVID-19): A Meta-Analysis

How to cite this article: Ghosal S. Selecting antihyperglycemic agents with proven safety: A must in COVID-19 era